Hepion Pharmaceuticals announced a significant leadership change with Dr. Kaouthar Lbiati resigning as CEO and Gary Stetz being appointed as the new CEO, alongside Vincent LoPriore as Executive Chairman. The company also reported a reduced net loss of $(0.81) million for Q1 2026, a substantial improvement from $(6.11) million in Q1 2025. This comes as the company pivots its focus from drug therapy to medical diagnostics, evidenced by a recent intellectual property license agreement with Cirna Diagnostics. Despite the improved financials, the company noted substantial doubt about its ability to continue as a going concern without additional capital, though it secured $700,000 in a private placement post-quarter end.
Hepion Pharmaceuticals Appoints New CEO; Reports Reduced Q1 Loss
